The prognostic value of TIMP-1 in multiple myeloma

Leukemia Research

Volumn 34, Issue 5, 2010, Pages 576-577

  Guedez, Liliana ^a   Stetler Stevenson, William G ^a  

^a NATIONAL CANCER INSTITUTE   (United States)

Author keywords

Multiple myeloma; TIMP 1

Indexed keywords

CYCLIN D2; HERMES ANTIGEN; INTERLEUKIN 10; INTERLEUKIN 6; STAT3 PROTEIN; SYNDECAN 1; TISSUE INHIBITOR OF METALLOPROTEINASE 1;

APOPTOSIS; B LYMPHOCYTE; CANCER GROWTH; CARCINOGENESIS; CELL DIFFERENTIATION; CELL PROLIFERATION; EDITORIAL; ENZYME ACTIVATION; ENZYME INHIBITION; GENE OVEREXPRESSION; MULTIPLE MYELOMA; PHENOTYPE; PLASMA CELL DYSCRASIA; PRIORITY JOURNAL; PROGNOSIS; PROTEIN BLOOD LEVEL; PROTEIN EXPRESSION; UPREGULATION;

ANIMALS; HUMANS; MULTIPLE MYELOMA; PROGNOSIS; TISSUE INHIBITOR OF METALLOPROTEINASE-1; TUMOR MARKERS, BIOLOGICAL;

EID: 77950080052     PISSN: 01452126     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.leukres.2009.10.005     Document Type: Editorial

References (25)

1. Frederiksen C., Lomholt A.F., Davis G.J., Dowell B.L., Blankenstein M.A., Christensen I.J., et al. Changes in plasma TIMP-1 levels after resection for primary colorectal cancer. Anticancer Res 2009, 29(1):75-81.
2. Holten-Andersen M.N., Brunner N., Nielsen H.J., Christensen I.J., Sorensen N.M., Rasmussen A.S., et al. Levels of tissue inhibitor of metalloproteinases 1 in plasma and urine from patients with bladder cancer. Int J Biol Markers 2006, 21(1):6-11.
3. Holten-Andersen M.N., Murphy G., Nielsen H.J., Pedersen A.N., Christensen I.J., Hoyer-Hansen G., et al. Quantitation of TIMP-1 in plasma of healthy blood donors and patients with advanced cancer. Br J Cancer 1999, 80(3-4):495-503.
4. Nakopoulou L., Giannopoulou I., Stefanaki K., Panayotopoulou E., Tsirmpa I., Alexandrou P., et al. Enhanced mRNA expression of tissue inhibitor of metalloproteinase-1 (TIMP-1) in breast carcinomas is correlated with adverse prognosis. J Pathol 2002, 197(3):307-313.
5. Terpos E., et al. High levels of serum TIMP-1 correlate with advanced disease and predict for poor survival in patients with multiple myeloma treated with novel agents. Leuk Res 2010, 34:399-402.
6. Robbiani D.F., Chesi M., Bergsagel P.L. Bone lesions in molecular subtypes of multiple myeloma. N Engl J Med 2004, 351(2):197-198.
7. Abildgaard N., Brixen K., Eriksen E.F., Kristensen J.E., Nielsen J.L., Heickendorff L. Sequential analysis of biochemical markers of bone resorption and bone densitometry in multiple myeloma. Haematologica 2004, 89(5):567-577.
8. Kyle R.A., Remstein E.D., Therneau T.M., Dispenzieri A., Kurtin P.J., Hodnefield J.M., et al. Clinical course and prognosis of smoldering (asymptomatic) multiple myeloma. N Engl J Med 2007, 356(25):2582-2590.
9. Tian E., Zhan F., Walker R., Rasmussen E., Ma Y., Barlogie B., et al. The role of the Wnt-signaling antagonist DKK1 in the development of osteolytic lesions in multiple myeloma. N Engl J Med 2003, 349(26):2483-2494.
10. Brew K., Dinakarpandian D., Nagase H. Tissue inhibitors of metalloproteinases: evolution, structure and function. Biochim Biophys Acta 2000, 1477(1-2):267-283.
11. Stetler-Stevenson W.G. Tissue inhibitors of metalloproteinases in cell signaling: metalloproteinase-independent biological activities. Sci Signal 2008, 1(27):6-8.
12. Docherty A.J., Lyons A., Smith B.J., Wright E.M., Stephens P.E., Harris T.J., et al. Sequence of human tissue inhibitor of metalloproteinases and its identity to erythroid-potentiating activity. Nature 1985, 318(6041):66-69.
13. Lambert E., Bridoux L., Devy J., Dasse E., Sowa M.L., Duca L., et al. TIMP-1 binding to proMMP-9/CD44 complex localized at the cell surface promotes erythroid cell survival. Int J Biochem Cell Biol 2009, 41(5):1102-1115.
14. Guedez L., Stetler-Stevenson W.G., Wolff L., Wang J., Fukushima P., Mansoor A., et al. In vitro suppression of programmed cell death of B cells by tissue inhibitor of metalloproteinases-1. J Clin Invest 1998, 102(11):2002-2010.
15. Guedez L., Lim M.S., Stetler-Stevenson W.G. The role of metalloproteinases and their inhibitors in hematological disorders. Crit Rev Oncog 1996, 7(3-4):205-225.
16. Li G., Fridman R., Kim H.R. Tissue inhibitor of metalloproteinase-1 inhibits apoptosis of human breast epithelial cells. Cancer Res 1999, 59(24):6267-6275.
17. Rhee J.S., Diaz R., Korets L., Hodgson J.G., Coussens L.M. TIMP-1 alters susceptibility to carcinogenesis. Cancer Res 2004, 64(3):952-961.
18. Yamada E., Tobe T., Yamada H., Okamoto N., Zack D.J., Werb Z., et al. TIMP-1 promotes VEGF-induced neovascularization in the retina. Histol Histopathol 2001, 16(1):87-97.
19. Liu H., Chen B., Lilly B. Fibroblasts potentiate blood vessel formation partially through secreted factor TIMP-1. Angiogenesis 2008, 11(3):223-234.
20. Cai G., Zhang X., Hong Q., Shao F., Shang X., Fu B., et al. Tissue inhibitor of metalloproteinase-1 exacerbated renal interstitial fibrosis through enhancing inflammation. Nephrol Dial Transplant 2008, 23(6):1861-1875.
21. Guedez L., Martinez A., Zhao S., Vivero A., Pittaluga S., Stetler-Stevenson M., et al. Tissue inhibitor of metalloproteinase 1 (TIMP-1) promotes plasmablastic differentiation of a Burkitt lymphoma cell line: implications in the pathogenesis of plasmacytic/plasmablastic tumors. Blood 2005, 105(4):1660-1668.
22. Bergsagel P.L., Kuehl W.M. Critical roles for immunoglobulin translocations and cyclin D dysregulation in multiple myeloma. Immunol Rev 2003, 194:96-104.
23. Guedez L., Mansoor A., Birkedal-Hansen B., Lim M.S., Fukushima P., Venzon D., et al. Tissue inhibitor of metalloproteinases 1 regulation of interleukin-10 in B-cell differentiation and lymphomagenesis. Blood 2001, 97(6):1796-1802.
24. Alexandrakis M.G., Passam F.J., Ganotakis E., Dafnis E., Dambaki C., Konsolas J., et al. Bone marrow microvascular density and angiogenic growth factors in multiple myeloma. Clin Chem Lab Med 2004, 42(10):1122-1126.
25. Singhal S., Mehta J., Desikan R., Ayers D., Roberson P., Eddlemon P., et al. Antitumor activity of thalidomide in refractory multiple myeloma. N Engl J Med 1999, 341(21):1565-1571.